Showing results 1 to 60 of 132
|A combination of cilostazol and Ginkgo biloba extract protects against cisplatin-induced Cochleo-vestibular dysfunction by inhibiting the mitochondrial apoptotic and ERK pathways.
|김유석, 임혜진, 정연훈
|A novel disintegrin salmosin inhibits tumor angiogenesis.
|A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis
|A rare case of chronic myelogenous leukemia and plasma cell myeloma in the same patient.
|박준성, 조성란, 한재호
|Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma.
|Adjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer
|강석윤, 김지훈, 노오규, 박래웅, 오영택, 윤덕용, 이현우, 전미선
|Altered intrinsic brain activity after chemotherapy in patients with gastric cancer: A preliminary study
|Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data
|강석윤, 김태환, 신승수, 안미선, 이현우, 최용원, 최진혁
|Asian Society of Gynecologic Oncology International Workshop 2018
|공태욱, 유희석, 장석준
|Attitudes toward participating in Phase I clinical trials: an investigation with patient-family-physician triads
|AY4, an agonistic anti-death receptor 4 MAB, induces apoptotic cell death in anaplastic thyroid cancer cells via downregulation of Bcl-xL with reactive oxygen species generation.
|김철호, 신유섭, 이복순
|Bacterial production and structure-functional validation of a recombinant antigen-binding fragment (Fab) of an anti-cancer therapeutic antibody targeting epidermal growth factor receptor
|Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells.
|Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma
|By activating Fas/ceramide synthase 6/p38 kinase in lipid rafts, stichoposide D inhibits growth of leukemia xenografts.
|Ca2+ influx-mediated dilation of the endoplasmic reticulum and c-FLIPL downregulation trigger CDDO-Me-induced apoptosis in breast cancer cells.
|Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities
|Cathepsin D and eukaryotic translation elongation factor 1 as promising markers of cellular senescence.
|Cdc2 and Cdk2 play critical roles in low dose doxorubicin-induced cell death through mitotic catastrophe but not in high dose doxorubicin-induced apoptosis.
|Cell cycle synchronisation using thiazolidinediones affects cellular glucose metabolism and enhances the therapeutic effect of 2-deoxyglucose in colon cancer
|박복남, 변혜은, 안영실, 윤준기, 이수진
|Chemotherapeutic drug, adriamycin, restores the function of p53 protein in hepatitis B virus X (HBx) protein-expressing liver cells.
|박선, 이재호, 조혜성
|Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
|Clinical Characteristics and Treatment Outcomes in Children, Adolescents, and Young-adults with Hodgkin's Lymphoma: a KPHOG Lymphoma Working-party, Multicenter, Retrospective Study
|Clinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group
|Clinical Impact of Escalating Relative High-dose-rate Intracavitary Brachytherapy Dose in Stage IIB Cervical Cancer
|노오규, 오영택, 장석준, 전미선, 조오연
|Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer
|Clinical predictors associated with proton pump inhibitor-induced hypomagnesemia.
|Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial.
|Combination versus single-agent as palliative chemotherapy for gastric cancer
|강석윤, 박준성, 신승수, 안미선, 이현우, 정성현, 최용원, 최진혁
|Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib
|Comparison of antiproliferative effects of 1-histamine-2 receptor antagonists, cimetidine, ranitidine, and famotidine, in gastric cancer cells.
|김진홍, 김효철, 이광재, 조성원, 함기백
|Concurrent chemoradiotherapy in patients with nasopharyngeal cancer: prognostic significance of low expression of bax.
|강석윤, 강승희, 김철호, 김효철, 박준성, 오영택, 이현우, 장준호, 전미선, 주희재, 최진혁, 한재호
|Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors.
|Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5).
|Desensitization Using Bortezomib and High-dose Immunoglobulin Increases Rate of Deceased Donor Kidney Transplantation
|Determinants of quality of life in women immediately following the completion of primary treatment of breast cancer: A cross-sectional study
|김지영, 박진희, 배선형, 정용식
|Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas
|김성수, 서해영, 장다영
|Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors
|Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
|Dual anticancer activity of 8-Cl-cAMP: inhibition of cell proliferation and induction of apoptotic cell death.
|Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.
|EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients
|강석윤, 고영화, 박준성, 신승수, 이현우, 정성현, 최용원, 최진혁, 한재호
|Epicatechin protects the auditory organ by attenuating cisplatin-induced ototoxicity through inhibition of ERK.
|김철호, 이진석, 정연훈
|Evolution of Machine Learning Algorithms in the Prediction and Design of Anticancer Peptides
|Balachandran, Manavalan, Basith, Shaherin, 신태환, 이광, 이다연
|Factors Influencing Posttraumatic Growth in Survivors of Breast Cancer
|Feasibility and accessibility of electronic patient-reported outcome measures using a smartphone during routine chemotherapy: a pilot study
|Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
|Feasibility of hyperthermic pressurized intraperitoneal aerosol chemotherapy in a porcine model
|Gambogic acid triggers vacuolization-associated cell death in cancer cells via disruption of thiol proteostasis
|Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma
|Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: Radiologic and clinical factors predictive of survival
|권요한, 김재근, 김진우, 원제환, 조효정, 허지미
|High SLC2A1 expression associated with suppressing CD8 T cells and B cells promoted cancer survival in gastric cancer
|Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib
|김보현, 김순선, 김재근, 신성재, 양민재, 유병무, 이광재, 이기명, 이제희, 임선교, 정재연, 조성원, 조효정, 황재철
|Highlights of the Twelfth Japan-Korea Joint Symposium on Cancer and Ageing Research.
|Histone deacetylase inhibitors induce mitochondrial elongation
|Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics.
|Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
|Imidazoline drugs stabilize lysosomes and inhibit oxidative cytotoxicity in astrocytes.
|Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis
|Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.